Physician profile
Caleb Robert Dulaney
NPI 1437592276
$2,464.32
in general payments reported to CMS, 2019-2025
46 companies · $509 in 2025
The $509 reported for 2025 was more than what 75% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $184 · 2021: $226 · 2022: $377 · 2023: $383 · 2024: $637 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,430 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.95 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $332.62 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $310.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $236.51 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $148.86 | 2019-2023 | Imfinzi, Enhertu |
| Teleflex LLC | $130.61 | 2025 | Barrigel |
| Incyte Corporation | $110.56 | 2019-2025 | Jakafi |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Lilly USA, LLC | $67.69 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $59.96 | 2023-2024 | |
| Glaxosmithkline, LLC. | $56.59 | 2023-2024 | Jemperli, Zejula |
| Amgen INC. | $55.41 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $55.21 | 2022-2024 | Prolaris |
| Intuitive Surgical, INC. | $50.17 | 2025 | |
| Emd Serono, INC. | $49.99 | 2021-2024 | Bavencio |
| Genzyme Corporation | $46.19 | 2022-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Dulaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.